Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 20/20 | 0.83 |
| ▸ | CHUK | O15111 | 3/20 | 0.76 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | PRKACG | P22612 | 1/20 | 0.58 |
| ▸ | PRKACB | P22694 | 1/20 | 0.58 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657731 | 0.91 | IKBKB (1.00) | IKBKBCHUKEPHA3NTRK1PRKACA | |
| SCHEMBL6282456 | 0.89 | IKBKB (0.86) | IKBKBCHUKEPHA3NTRK1 | |
| SCHEMBL6282321 | 0.87 | IKBKB (0.70) | IKBKBCHUKEPHA3NTRK1 | |
| SCHEMBL4656802 | 0.87 | IKBKB (1.00) | IKBKBCHUKEPHA3NTRK1PRKACA | |
| SCHEMBL4657117 | 0.86 | IKBKB (1.00) | IKBKBCHUKEPHA3NTRK1 | |
| SCHEMBL6278570 | 0.86 | IKBKB (0.68) | IKBKBCHUKEPHA3NTRK1 | |
| SCHEMBL6276911 | 0.86 | IKBKB (0.68) | IKBKBCHUKEPHA3NTRK1 | |
| SCHEMBL4659222 | 0.86 | IKBKB (0.68) | IKBKBCHUKEPHA3NTRK1 | |
| SCHEMBL6276397 | 0.85 | IKBKB (0.68) | IKBKBCHUKEPHA3NTRK1 | |
| SCHEMBL4658222 | 0.85 | IKBKB (1.00) | IKBKBCHUKEPHA3NTRK1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | US | claimed |
| US-6974870-B2 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHAMACEUTICALS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, IKBKB, CHUK | IKBKB 2/4885CHUK 3/4885EPHA3 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.